VGAIT for Chemotherapy-induced Peripheral Neuropathy

Inclusion Criteria:

* at least 18 years of age
* have histologically confirmed stage I-III breast cancer,
* have completed adjuvant taxane-based chemotherapy (alone or in combination), ,
* have an Eastern Cooperative Oncology Group performance status of 0 or 1, and reported grade 1 or greater CIPN symptoms for more than 2 weeks as defined by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.03.

Exclusion Criteria:

* concurrent chemotherapy (there were no limitations on time from the last paclitaxel administration),
* having metastatic or recurrent disease,
* history of preexisting peripheral neuropathy prior to chemotherapy,
* uncontrolled seizure disorder,
* unstable cardiac disease or myocardial infarction within 6 months prior to study entry, being pregnant or nursing, or having used acupuncture for CIPN within 6 months prior to study entry.